Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) for Glaucoma

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
University of Maryland, Baltimore, Baltimore, MD
Glaucoma
Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 years

3 years
Autoregulation of retinal blood flow

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Isocapnic Oxygen
1 of 1
Experimental Treatment

90 Total Participants · 1 Treatment Group

Primary Treatment: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO) · No Placebo Group · Phase 4

Isocapnic OxygenExperimental Group · 3 Interventions: Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO), Isocapnic Oxygen, Indocyanine Green Angiography · Intervention Types: DiagnosticTest, Biological, DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
Closest Location: University of Maryland, Baltimore · Baltimore, MD
Photo of Baltimore 1Photo of Baltimore 2Photo of Baltimore 3
2020First Recorded Clinical Trial
1 TrialsResearching Glaucoma
52 CompletedClinical Trials

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
594 Previous Clinical Trials
332,412 Total Patients Enrolled
1 Trials studying Glaucoma
10 Patients Enrolled for Glaucoma

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a minimum age of 18 years.\n\n- ClinicalTrials.
You have a gonioscopy grade 3 or 4.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.